Cagrilintide dosage: reported doses and schedule

Typical reported dose: 0.25 mg once a week to start, up to 2.4 mg

• Phase 2: 0.3 mg: 0.3 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with obesity or overweight with hypertension/dyslipidemia; no diabetes. (source)
• Phase 2: 0.6 mg: 0.6 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with obesity or overweight with hypertension/dyslipidemia; no diabetes. (source)
• Phase 2: 1.2 mg: 0.6 mg once weekly, then 1.2 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with obesity or overweight with hypertension/dyslipidemia; no diabetes. (source)
• Phase 2: 2.4 mg: 0.6 mg once weekly, then 1.2 mg once weekly, then 2.4 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with obesity or overweight with hypertension/dyslipidemia; no diabetes. (source)
• Phase 2: 4.5 mg: 0.6 mg once weekly, then 1.2 mg once weekly, then 2.4 mg once weekly, then 4.5 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with obesity or overweight with hypertension/dyslipidemia; no diabetes. (source)
• Diabetes trial: 2.4 mg: 0.25 mg once weekly, then 0.5 mg once weekly, then 1 mg once weekly, then 1.7 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes and BMI ≥27 on metformin, with or without an SGLT2 inhibitor. (source)

Highest studied: Highest verified published SC weekly cagrilintide target: 4.5 mg..

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator